Compare Novavax Inc (NVAX) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard High Dividend Yield ETF — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while Vanguard High Dividend Yield ETF trades at $160.5. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | VYM | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | — |
52-Week High | $11.19 | $161.17 |
52-Week Low | $6.22 | $132.90 |
Enterprise Value | $800.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
VYM trades at $159.41, down 0.47% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds $94.6 billion in assets and focuses on high dividend yield from US large-cap stocks, offering broad diversification and a low expense ratio. Recent news highlights institutional buying and its role in retirement income strategies.
The outlook for VYM is supported by strong dividend income appeal and institutional interest, but risks include interest rate sensitivity and competition from other dividend ETFs. Its low-cost structure and yield focus position it as a core holding for income-seeking investors, though market volatility could pressure returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
